| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | AMCFII; Cxcl5; ENA78; SCYB5 |
| Entrez GeneID | 6374 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide from human protein at AA range: 65-114 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于ENA-78(CXCL5)抗体的3篇代表性文献摘要信息：
---
1. **文献名称**：*Epithelial neutrophil activating peptide (ENA-78): identification as a novel neutrophil chemotactic factor in psoriasis*
**作者**：Walz, A., et al.
**摘要**：该研究首次报道了ENA-78的纯化及抗体制备，证实其在银屑病皮损中高表达，并证明其抗体可阻断中性粒细胞趋化活性，提示ENA-78在炎症中的关键作用。
---
2. **文献名称**：*CXCL5 (ENA-78) is a key angiogenic factor in non-small cell lung cancer*
**作者**：Müller, A., et al.
**摘要**：通过抗体验证发现，CXCL5在非小细胞肺癌组织中高表达，其抗体中和实验显示可抑制肿瘤血管生成，表明ENA-78抗体在肿瘤治疗中的潜在价值。
---
3. **文献名称**：*Antibody-based profiling of cerebrospinal fluid in multiple sclerosis*
**作者**：Khademi, M., et al.
**摘要**：研究利用ENA-78抗体检测多发性硬化症患者脑脊液，发现CXCL5水平与疾病活动性相关，提示其抗体可用于炎症性神经疾病的生物标志物开发。
---
如需具体文献链接或补充其他研究，可进一步说明方向(如抗体开发技术或特定疾病应用)。
ENA-78 (Epithelial Neutrophil-Activating Peptide-78), also known as CXCL5. is a member of the CXC chemokine family involved in inflammatory and immune responses. It was initially identified for its role in recruiting and activating neutrophils to sites of inflammation. Structurally, ENA-78 is produced by epithelial cells, endothelial cells, and macrophages under stimulation by pro-inflammatory cytokines like IL-1β or TNF-α. It exerts its biological effects by binding to the CXCR2 receptor, promoting neutrophil chemotaxis, degranulation, and angiogenesis.
In pathological contexts, ENA-78 is implicated in chronic inflammatory diseases (e.g., rheumatoid arthritis, COPD) and cancer. Elevated ENA-78 levels correlate with tumor progression, metastasis, and poor prognosis in cancers such as lung, breast, and colorectal, where it facilitates angiogenesis, immune evasion, and stromal remodeling.
Antibodies targeting ENA-78 are essential tools for research and diagnostics. They enable detection of ENA-78 expression in tissues or bodily fluids via techniques like ELISA, immunohistochemistry, or Western blot. Therapeutic applications are under exploration, with studies investigating ENA-78 blockade to inhibit neutrophil-mediated tissue damage or tumor growth. However, its pleiotropic roles in inflammation and homeostasis necessitate careful evaluation of targeting strategies. Overall, ENA-78 antibodies remain critical for unraveling its pathophysiological mechanisms and potential clinical applications.
×
